Price (delayed)
$0.503
Market cap
$58.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.88
Enterprise value
-$58.74M
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative
There are no recent dividends present for ALVR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.